Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 551 - 600 out of 115,935

Document Document Title
WO/2023/232882A1
A nutritional composition comprising digestible carbohydrates, protein and lipid, wherein the lipid comprises phospholipids, for use in improving the cognitive development in an infant born to a mother with hyperglycemia during pregnancy.  
WO/2023/235500A1
A method of reducing the risk of a cocaine‐addicted subject relapsing in addiction is provided, the method including administering to the subject a combination of an effective amount of humanized 2E2 (h2E2) monoclonal antibody and an e...  
WO/2023/233183A1
The present invention relates to the field of medicaments. Particularly, the present invention refers to the combination of cannabidiol (CBD) and resveratrol at a specific dosage regimen and related application with "entourage effect-lik...  
WO/2023/233164A1
Compounds of formula (I) wherein R1, R2 and R3 are as defined herein are able to rescue dysfunctional mitochondria and are therefore of use in the treatment and prevention of neurodegenerative disorders as well as acute radiation syndrom...  
WO/2023/233437A1
The present invention relates to some RNA sequences which have been found effective in the treatment of a neurological disorder. Specifically, the neurological disorder is an autism spectrum disorder or autism and/or epilepsy.  
WO/2023/235726A2
Guide RNAs and CRISPR/Cas systems targeting a C9orf72 gene, lipid nanoparticles or viral vectors comprising such CRISPR/Cas systems, and cells or animals comprising such CRISPR/Cas systems are provided. Methods of repressing transcriptio...  
WO/2023/233665A1
Provided are: an immunocyte activator containing, as an active ingredient, a substance which inhibits the binding of fibronectin and an immunosuppressive receptor LILRB4; and a therapeutic agent for immunocyte-related inflammatory diseas...  
WO/2023/230718A1
The present invention provides a method of determining the amount of a psilocybin in a sample, the method comprising contacting a cell which expresses ABCF1 with the sample, comparing the expression of ABCF1 with a standard to determine ...  
WO/2023/235648A1
Methods and compositions for nuclear delivery and transcriptional repression employ a cell-penetrant MeCP2 fusion protein.  
WO/2023/235319A1
Glycosylated, cyclic peptides of Formula (I): A1-cyclo[A2-A3-A4-A5]-A6-O-Carb, Formula (II): A1-cyclo[A5-A3-A4-A2]-A6-O-Carb, and pharmaceutically acceptable salts thereof, are described herein, which are useful, e.g., in treating pain. ...  
WO/2023/235433A1
Disclosed embodiments concern novel interleukin receptor associated kinases (IRAK) inhibitor compounds and compositions comprising such compounds. The compounds may have a structure according to Formula (I). Also disclosed are methods of...  
WO/2023/234330A1
The present invention addresses the problem of providing an EGFR CAR-T cell which is expected to be effective against a tumor in which an EGFR is expressed. The present invention provides: a polynucleotide encoding a chimeric antigen rec...  
WO/2023/234620A1
The present invention relates to a novel strain having resistance to methylglyoxal and activity to reduce advanced glycation end products (AGEs), and a composition including the strain. The strain and the composition not only have resist...  
WO/2023/233329A1
The present disclosure relates to methods of treating cocaine addiction by administrating 5-methoxy-2-aminoindan, or a salt thereof, to a subject in need thereof in a therapeutically effective amount. The disclosure also relates to metho...  
WO/2023/230649A1
The present disclosure relates to compounds of formula (I), their methods of synthesis, and their use in the treatment of mental illness or central nervous system disorders.  
WO/2023/232966A1
Provided herein are compounds of Formula (I), (I), or pharmaceutically acceptable salt thereof, wherein m, n, p, A1, A2, A3, A4, L, R1, R2, R3, R4, Formula (II), (II), V, X, Y and Z are defined herein. Also provided herein are pharmaceut...  
WO/2023/232764A1
The invention provides methods of treatment of a neurodegenerative disease in a subject, which methods comprise orally administering to said subject a methylthioninium (MT) containing compound, wherein said administration is at a dosage ...  
WO/2023/233051A1
The invention relates to prolonged-release injectable compositions for use in a method for treating a disease, disorder or condition sensitive to risperidone or to paliperidone with risperidone in a patient who receives one or more inhib...  
WO/2023/231948A1
Disclosed are a class of ISR inhibitors, a method for preparing same, and use thereof. The present invention belongs to the technical field of biopharmaceutics. The compound of the present invention is a compound having a structure of fo...  
WO/2023/235880A1
The disclosure provides compounds of Formula (I) and salts thereof for use in medical treatment.  
WO/2023/235725A2
Nuclease agents, including guide RNAs and CRISPR/Cas systems, targeting a C9orf72 gene, lipid nanoparticles or viral vectors comprising such nuclease agents, and cells or animals comprising such nuclease agents are provided. Methods of m...  
WO/2023/235548A1
Squaramide-based cannabinoid 1 receptor (CB1R) allosteric modulators are described. Exemplary analogs may provide improved potencies and pharmacokinetic properties. Methods of using the analogs to treat diseases mediated by CB1R, such as...  
WO/2023/235541A1
In an aspect, the disclosure relates to a liquid pharmaceutical composition comprising, consisting essentially of, or consisting of gemfibrozil and an aqueous solvent. The disclosure also relates to methods of making the liquid pharmaceu...  
WO/2023/231778A1
Provided are a transgenic expression cassette capable of treatment of mucopolysaccharidosis type IIIA, an application thereof, an optimized nucleic acid molecule encoding N-sulfoglucosamine sulfohydrolase (SGSH), a designed and optimized...  
WO/2023/234166A1
This antiepileptic composition contains one of or both of a bacterium of the genus Bifidobacterium and a culture thereof. The bacterium of the genus Bifidobacterium may be Bifidobacterium breve. The bacterium of the genus Bifidobacterium...  
WO/2023/235790A1
The present disclosure relates to recombinant polypeptides and uses thereof for treating, preventing, and detecting inflammatory diseases. Specifically, the disclosure provides a recombinant polypeptide comprising an IL-2 polypeptide, a ...  
WO/2023/233395A1
The present invention provides extracellular vesicles (EVs) loaded with conjugates of an active agent and a hydrophilic compound such as a carbohydrate, methods for preparation and loading of said EVs, composition comprising the EVs and ...  
WO/2023/232171A1
Title of the invention: Heterocyclic compounds for the prevention and therapy of circadian rhythm disorders The present invention provides heterocyclic compounds of general formula I (I) and their pharmaceutically acceptable salts, where...  
WO/2023/234675A1
The present invention relates to antisense oligomers against monoamine oxidase B and a use thereof, and to: antisense oligomers that regulate the amount of genes, specifically, mRNA or protein, that code for monoamine oxidase B; and a us...  
WO/2023/234312A1
Antibody preparations for treating autoimmune-type diseases such as autoimmune diseases, allergic diseases, and kidney diseases in which autoimmunity is involved have been proposed, but the administration route thereof has been limited t...  
WO/2023/231346A1
Disclosed is use of N1-dihydrocaffeoyl-N10-caffeoyl spermidine in preparing a drug, a health care product or functional food. The present invention belongs to the technical field of drug chemistry. In a dosage range of 2-100 mg/kg given ...  
WO/2023/207574A9
Provided is a fusion protein, comprising: a transferrin-binding protein, and arylsulfatase A (ARSA) or a functional active fragment thereof. The transferrin-binding protein comprises a polypeptide, an antibody or an antigen-binding fragm...  
WO/2023/235785A1
The present disclosure relates to methods for the treatment of depressive disorders (e.g., major depressive disorder) with 1,2,4-triazolone derivatives. In some embodiments, the methods include selecting a human subject for treatment of ...  
WO/2023/234759A1
The present invention relates to a sulfanone derivative or a pharmaceutically acceptable salt thereof, and a composition containing the derivative as an active ingredient for the prevention or treatment of cancer, and the sulfanone deriv...  
WO/2023/227881A1
The present invention relates to the compound 4-(6-oxo-2-(trifluoromethyl)-3,6- dihydrochromeno[7,8-d]imidazol-8- yl)benzonitrile, also known as CF3CN, referred to herein as the compound of Formula I, for use in the treatment of diseases...  
WO/2023/230451A2
Provided is a method for treating spinocerebellar ataxia genotype type 3 in a patient in need thereof, including administering to the patient a dosage form comprising an effective amount of troriluzole hydrochloride monohydrate. Also pro...  
WO/2023/228107A1
The present invention concerns a composition comprising, as active ingredients: - dry extract of Withania somnifera, - dry extract of Melissa officinalis, - microencapsulated essential oil of Lavandula angustifolia, and - optionally, Vit...  
WO/2023/230282A1
Described herein are methods and compositions for treating neurodegenerative diseases including Spinocerebellar Ataxia comprising administering a BACE1 inhibitor.  
WO/2023/227731A1
The present invention relates to a set of peptides, to compositions and kits comprising or allowing the expression of said peptides, as well as to uses thereof, in particular for preventing or treating pain in a subject in need thereof.  
WO/2023/227695A1
The invention relates to compounds that are useful for the prevention or treatment of TRPM3 mediated disorders, more in particular disorders selected from pain, epilepsy and inflammatory hypersensitivity. The invention also relates to a ...  
WO/2023/228154A1
Provided herein are methods of treating a patient, such as a human patient, having inflammation or an inflammatory disease or a disease in which inflammation is present, such as cardiovascular or vascular endothelium inflammation, such a...  
WO/2023/228766A1
According to the present invention, an oral solid formulation is coated with a rapid disintegration gel coating that contains an acidic substance, a carbonate, and a polymer that turns into a gel through contact with moisture. As a resul...  
WO/2023/227696A1
The invention relates to compounds that are useful for the prevention or treatment of TRPM3 mediated disorders, more in particular disorders selected from pain, epilepsy and inflammatory hypersensitivity. The invention also relates to a ...  
WO/2023/229445A1
The present invention relates to a novel peptide, and a use thereof, and more specifically, provides: a novel peptide comprising an H-G-X1-X2-G-X3 structure and having a length of 4 to 10 a.a., the peptide having the ability to inhibit t...  
WO/2023/228155A1
Long-acting glucagon like peptide 1 receptor agonists (GLP-1r agonists) reduce and inhibit pathological processes that give rise to long-term neurological impairment. A biotinylated and/or lipidated GLP-1r agonist analogs with enhanced e...  
WO/2023/227070A1
The present disclosure relates to a double-stranded ribonucleic acid for inhibiting C3 gene expression, a modifier, a conjugate, and a use thereof. Specifically, the present disclosure relates to a double-stranded ribonucleic acid, a dou...  
WO/2023/226873A1
Provided are a recombinant BoNT/A and a preparation method thereof. The recombinant BoNT/A is a BoNT/A mutant, the BoNT/A mutant comprising a first peptide fragment and a second peptide fragment, which are linked through an interchain di...  
WO/2022/226191A9
The disclosure provides method of enhancing neuronal, vascular cell, and macrophage proteostasis, in a subject by administering a CMA activator to the subject. Enhancing proteostasis is a method of preventing or slowing advancement of an...  
WO/2023/229034A1
The present invention provides an FPR2 agonist. More specifically, the FPR2 agonist contains, as an active ingredient, outer membrane vesicles derived from at least one lactic acid bacterium selected from the group consisting of lactic a...  
WO/2023/230375A1
The present disclosure provides methods of treating a neuropathophysiological condition in a patient in need thereof. The patient can be treated with an effective amount of a cannabinoid.  

Matches 551 - 600 out of 115,935